Increased expression of 5-hydroxytryptamine(2A/B) receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention

Episode von Medizin - Open Access LMU - Teil 17/22 von Ludwig-Maximilians-Universität München · 1. Januar 2010

Background

Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limited responsiveness to available treatments. It is characterised by epithelial cell injury, fibroblast activation and proliferation and extracellular matrix deposition. Serotonin (5-hydroxytryptamine; 5-HT) induces fibroblast proliferation via the 5-HTR2A and 5-HTR2B receptors, but its pathophysiological role in IPF remains unclear. A study was undertaken to determine the expression of 5-HT receptors in IPF and experimental lung fibrosis and to investigate the effects of therapeutic inhibition of 5-HTR2A/B signalling on lung fibrosis in vivo and in vitro.

Methods and results

Quantitative RT-PCR showed that the expression of 5-HTR1A/B and 5-HTR2B was significantly increased in the lungs of patients with IPF (n = 12) and in those with non-specific interstitial pneumonia (NSIP, n = 6) compared with transplant donors (n = 12). The expression of 5-HTR2A was increased specifically in IPF lungs but not in NSIP lungs. While 5-HTR2A protein largely localised to fibroblasts, 5-HTR2B localised to the epithelium. To assess the effects of 5HTR(2A/B) inhibition on fibrogenesis in vivo, mice were subjected to bleomycin-induced lung fibrosis and treated with the 5-HTR2A/B antagonist terguride (or vehicle) in a therapeutic approach (days 14-28 after bleomycin). Terguride-treated mice had significantly improved lung function and histology and decreased collagen content compared with vehicle-treated mice. Functional in vitro studies showed that terguride is a potent inhibitor of transforming growth factor beta(1)- or WNT3a-induced collagen production.

Conclusion

The studies revealed an increased expression of 5-HTR2A specifically in IPF. Blockade of 5-HTR2A/B signalling by terguride reversed lung fibrosis and is thus a promising therapeutic approach for IPF.

Weitere Episoden von „Medizin - Open Access LMU - Teil 17/22“

• 200 years Organon of Medicine - A comparative Review of its six editions (1810-1842) 1. Januar 2010
• A powerful transgenic tool for fate mapping and functional analysis of newly generated neurons 1. Januar 2010
• Air temperature and inflammatory and coagulation responses in men with coronary or pulmonary disease during the winter season 1. Januar 2010
• Ambient particulate pollution and the world-wide prevalence of asthma, rhinoconjunctivitis and eczema in children: Phase One of the International Study of Asthma and Allergies in Childhood (ISAAC) 1. Januar 2010
• Amiloride reduces portal hypertension in rat liver cirrhosis 1. Januar 2010
• Association between exposure to radiofrequency electromagnetic fields assessed by dosimetry and acute symptoms in children and adolescents: a population based cross-sectional study 1. Januar 2010
• Bone Morphogenetic Protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis 1. Januar 2010
• Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome 1. Januar 2010
• Deqi sensations without cutaneous sensory input: results of an RCT 1. Januar 2010
• Diagnostic indices for vertiginous diseases 1. Januar 2010
• How large are the nonspecific effects of acupuncture? A meta-analysis of randomized controlled trials 1. Januar 2010
• Impact of the indexed effective orifice area on mid-term cardiac-related mortality after aortic valve replacement 1. Januar 2010
• LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer 1. Januar 2010
• Minocycline is cytoprotective in human corneal endothelial cells and induces anti-apoptotic B-cell CLL/lymphoma 2 (Bcl-2) and X-linked inhibitor of apoptosis (XIAP) 1. Januar 2010
• Molecular characterisation of congenital myasthenic syndromes in Southern Brazil 1. Januar 2010

Alle Episoden von Medizin - Open Access LMU - Teil 17/22 · Mehr Bildung-Podcasts